T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2726
SGHC Ltd
SGHC
$6.64B
| $81K | ﹤0.01% |
+27,660
| New | +$97.8K |
|
2727
Teekay
TK
$1.06B
| $81K | ﹤0.01% |
13,397
| – | – |
|
2728
Inseego
INSG
$78.2M
| $79K | ﹤0.01% |
12,270
-1,490
| -11% | -$11.9K |
|
|
ONL
2729
Orion Office REIT
ONL
$158M
| $79K | ﹤0.01% |
11,866
+1,084
| +10% | +$6.76K |
|
2730
Fossil Group
FOSL
$330M
| $78K | ﹤0.01% |
30,055
-19,084
| -39% | -$52.4K |
|
2731
Akebia Therapeutics
AKBA
$242M
| $76K | ﹤0.01% |
82,800
-22,700
| -22% | -$21.9K |
|
2732
Vanda Pharmaceuticals
VNDA
$305M
| $76K | ﹤0.01% |
11,429
+1,049
| +10% | +$6.72K |
|
|
XXII
2733
22nd Century Group
XXII
$1.42M
| – | – |
0
| – | – |
|
|
VIA
2734
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
| $76K | ﹤0.01% |
10,880
-7,049
| -39% | -$84.1K |
|
2735
Aemetis
AMTX
$126M
| $75K | ﹤0.01% |
10,100
-9,896
| -49% | -$37.6K |
|
2736
FTAI Infrastructure
FIP
$547M
| $75K | ﹤0.01% |
+20,082
| New | +$65.2K |
|
2737
Standard BioTools
LAB
$302M
| $75K | ﹤0.01% |
38,400
-12,300
| -24% | -$24.3K |
|
|
OLPX
2738
DELISTED
Olaplex Holdings
OLPX
| $75K | ﹤0.01% |
19,905
+461
| +2% | +$1.69K |
|
2739
Babcock & Wilcox
BW
$1.4B
| $74K | ﹤0.01% |
12,466
+1,124
| +10% | +$6.59K |
|
|
MCHB
2740
Mechanics Bancorp
MCHB
$3.78B
| $74K | ﹤0.01% |
12,378
| – | – |
|
2741
PDS Biotechnology
PDSB
$13M
| $74K | ﹤0.01% |
+14,587
| New | +$95.5K |
|
2742
Rallybio
RLYB
$89.9M
| $74K | ﹤0.01% |
+1,596
| New | +$78.2K |
|
2743
NuScale Power
SMR
$4.08B
| $74K | ﹤0.01% |
+10,867
| New | +$88.2K |
|
2744
W&T Offshore
WTI
$543M
| $74K | ﹤0.01% |
19,026
+513
| +3% | +$2.21K |
|
2745
Workhorse Group
WKHS
$34.7M
| $73K | ﹤0.01% |
28
| – | – |
|
|
SYRS
2746
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $72K | ﹤0.01% |
22,550
| – | – |
|
|
DRRX
2747
DELISTED
DURECT Corp
DRRX
| $71K | ﹤0.01% |
14,210
| – | – |
|
2748
Aqua Metals
AQMS
$9.78M
| $70K | ﹤0.01% |
299
| – | – |
|
|
EU
2749
enCore Energy
EU
$227M
| $70K | ﹤0.01% |
+28,727
| New | +$64.1K |
|
2750
Fulcrum Therapeutics
FULC
$285M
| $70K | ﹤0.01% |
21,200
-15,261
| -42% | -$44.8K |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.